CuraCell Publishes Third and Final Clinical Report from CytoPLY™ Named-Patient Program, Demonstrating Tumour Responses Across Multiple Difficult-to-Treat Solid Tumours
Stockholm, Sweden - CuraCell TX AB (CuraCell) today announced the publication in Cytotherapy of the third and final scientific report emerging from its CytoPLY™ named-patient treatment program. The latest publication, “Targeting Intratumoral Heterogeneity in Pancreatic Cancer with Sequential TIL Infusions” adds pancreatic ductal adenocarcinoma (PDAC) to a growing body of clinical evidence supporting the potential of personalized tumour-infiltrating lymphocyte (TIL) therapy in heavily pretreated solid tumours.
Together, the three publications summarize clinical observations from named-patient treatments performed using CytoPLY-derived therapies across multiple advanced cancers with limited treatment options.
Across these patients, encouraging clinical activity was observed, including:
• Two complete responses: metastatic prostate cancer (>5 years ongoing remission) and recurrent glioblastoma
• Two partial responses: pancreatic cancer and renal cell carcinoma
• Additional evidence of biological activity supporting continued development in refractory solid tumours
The publications collectively demonstrate durable anti-tumour activity, long-term immune persistence, and the ability of personalized T-cell therapies to address challenges such as tumour heterogeneity and immune resistance in cancers traditionally considered difficult to treat with immunotherapy.
The latest PDAC publication provides translational evidence that sequential TIL infusions can broaden anti-tumour immune responses and potentially address intratumoral heterogeneity, a major obstacle in pancreatic cancer treatment. The reported patient achieved a partial response accompanied by immunological findings supporting the biological activity of the infused T-cell products.
“These three publications represent an important scientific milestone for CuraCell and provide a unique translational dataset generated from real-world named-patient treatments,” said Lucas Arruda, Chief Scientific Officer and co-author across the studies. “Across prostate cancer, glioblastoma and pancreatic cancer, we consistently observed evidence that transferred T cells can persist, infiltrate tumours, and contribute to clinically meaningful responses. Importantly, the pancreatic cancer study highlights how sequential TIL products may help overcome intratumoral heterogeneity, one of the key barriers limiting treatment success in solid tumours. Together, these findings strengthen the scientific rationale for advancing next-generation personalized cell therapies into broader clinical development.”
Reflecting on the overall experience from the named-patient program, Martin Forster, Board Member and Clinical Advisor, commented:
“While the patient numbers remain limited, the collective experience from the named-patient treatments provide important clinical insights. Across these heavily pretreated patients, we observed evidence of durable disease control and objective responses in tumour types where treatment options are often exhausted. Taken together, these findings support more formalised evaluation of personalised TIL therapies and suggest that meaningful clinical benefit may be achievable even in cancers traditionally considered resistant to immunotherapy.”
Commenting specifically on the patient perspective, Forster added:
“For patients with advanced cancers who have exhausted standard treatment options, even the possibility of durable disease control changes expectations. What stands out in these reports is not only the observation of tumour responses, but the duration of benefit in selected patients. This is ultimately the outcome that matters most - creating opportunities for longer survival and improved quality of life.”
Building on these findings, CuraCell is advancing CytoPLY™ through CC-38, currently being evaluated in an ongoing Phase I/IIa clinical trial in colorectal and prostate cancer.
About CuraCell
CuraCell is developing next-generation personalized cellular immunotherapies designed to expand the impact of adoptive T-cell treatment across solid tumours with high unmet medical need.
Scientific publications supporting this release:
• Serial TIL infusions and PD-1 blockade drive long-term clonal persistence in prostate cancer
• Tumor-infiltrating lymphocytes-derived CD8+ clonotypes infiltrate tumor tissue and mediate regression in glioblastoma
• Targeting Intratumoral Heterogeneity in Pancreatic Cancer with Sequential TIL Infusions
